Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAFV600E: implications for carcinogenesis and molecular therapy.

Molecular cancer therapeutics - 1 Mar 2011

Cantwell-Dorris Emma R, O'Leary John J, Sheils Orla M

Abstract excerpt

The mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway is frequently mutated in human cancer. This pathway consists of a small GTP protein of the RAS family that is activated in response to extracellular signaling to recruit a member of the RAF kinase family to the cell membrane. Active RAF signals through MAP/ERK kinase to activate ERK and its downstream effectors to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mice
Share to Cell Transformation, Neoplastic
Share to Extracellular Signal-Regulated MAP Kinases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to KRAS gene

Share to Mitogen-Activated Protein Kinases

Share to Molecular Targeted Therapy

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 21388974
DOI: 10.1158/1535-7163.MCT-10-0799

Genes

BRAF
KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAFV600E: implications for carcinogenesis and molecular therapy.PMID 21388974Read ↗

BRAF as a target for cancer therapy.Semantic proximity Read ↗

BRAF: A Two-Faced Janus.Semantic proximity Read ↗

BRAF mutation and its inhibitors in sarcoma treatment.Semantic proximity Read ↗

BRAF mutations in melanoma and colorectal cancer: a single oncogenic mutation with different tumour phenotypes and clinical implications.Semantic proximity Read ↗

Targeting the multifaceted BRAF in cancer: New directions.Semantic proximity Read ↗

Targeting the MAPK–RAS–RAF signaling pathway in cancer therapySemantic proximity Read ↗

BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future PerspectivesSemantic proximity Read ↗

BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies.Semantic proximity Read ↗

Molecular Pathways and Mechanisms of BRAF in Cancer Therapy.Semantic proximity Read ↗

Emerging BRAF Mutations in Cancer Progression and Their Possible Effects on Transcriptional Networks.Semantic proximity Read ↗

BRAF Mutation in Colorectal Cancer: An UpdateSemantic proximity Read ↗

Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.